Evidence map›Paper›PMID 38345718›Full record

Observational studyAnnals of surgical oncology2024

A Prospective Study of Sentinel Node Biopsy Omission in Women Age ≥ 65 Years with ER+ Breast Cancer.

Alice P Chung, Catherine M Dang, Scott R Karlan, Farin F Amersi, Edward M Phillips, Marissa K Boyle, Yujie Cui, Armando E Giuliano

Registry-linked trialOpen access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02564848 (IIT2015-06-Chung), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02564848 naactive not recruitingnot on this map

IIT2015-06-Chung: Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Clinical T1-2 Estrogen-Positive Breast Cancer Over Age 65

TypeinterventionalSponsorCedars-Sinai Medical CenterRan2016 to 2029Enrolled200ConditionsBreast CancerArmsLumpectomy without sentinel node biopsy
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. De-escalation of axillary treatment in early breast cancer-a narrative review of current trials.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2025
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Alice P ChungDepartment of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA. alice.chung@cshs.org.
Catherine M DangDepartment of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Scott R KarlanDepartment of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Farin F AmersiDepartment of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Edward M PhillipsDepartment of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Marissa K BoyleDepartment of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Yujie CuiDepartment of Statistics, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Armando E GiulianoDepartment of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Cedars-Sinai Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNational guidelines recommend omitting SNB in older patients with favorable invasive breast cancer. However, there is a lack of prospective data specifically addressing this issue. This study evaluates recurrence and survival in estrogen receptor-positive/Her2- (ER+) breast cancer patients, aged ≥ 65 years who have breast-conserving surgery (BCS) without SNB.

methodsThis is a prospective, observational study at a single institution where 125 patients aged ≥ 65 years with clinical T1-2N0 ER+ invasive breast cancer undergoing BCS were enrolled. Patients were treated with BCS without SNB. Primary outcome measure was axillary recurrence. Secondary outcome measures include recurrence-free survival (RFS), disease-free survival (DFS), breast cancer-specific survival (BCSS), and overall survival (OS).

resultsFrom January 2016 to July 2022, 125 patients were enrolled with median follow-up of 36.7 months [95% confidence interval (CI) 35.0-38.0]. Median age was 77.0 years (range 65-93). Median tumor size was 1 cm (range 0.1-5.0). Most tumors were ductal (95/124, 77.0%), intermediate grade (60/116, 51.7%), and PR-positive (117/123, 91.7%). Radiation therapy was performed in 37 of 125 (29.6%). Only 60 of 125 (48.0%) who were recommended hormonal therapy were compliant at 2 years. Chemotherapy was administered to six of 125 (4.8%) patients. There were two of 125 (1.6%) axillary recurrences. Estimated 3-years rates of regional RFS, DFS, and OS were 98.2%, 91.2%, and 94.8%, respectively. Univariate Cox regression identified hormonal therapy noncompliance to be significantly associated with recurrence (p = 0.02).

conclusionsAxillary recurrence rates were extremely low in this cohort. These results provide prospective data to support omission of SNB in this patient population

trial registrationClinicalTrials.gov ID NCT02564848.

Indexed as

Breast NeoplasmsAgedAged, 80 and overAxillaFemaleFollow-Up StudiesHumansLymph Node ExcisionMastectomy, SegmentalNeoplasm Recurrence, LocalProspective StudiesSentinel Lymph Node BiopsyAge over 65Breast cancerBreast conserving surgeryEstrogen-receptor positiveSentinel node biopsy

Identifiers

PMID38345718
PMCPMC10997698
OpenAlexW4391755736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.